OSEL Devices (OSELDEVICE)

FairStock Score: 56/100 — STEADY

Score breakdown: P/E: 0/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 68.13% and profit growth of 89.64% show exceptional momentum
• ROCE of 31.14% indicates strong capital efficiency and a competitive edge
• Promoter holding of 65.21% aligns management interests with minority shareholders
• Piotroski F-Score of 7/9 points to solid overall financial health

Concerns

• P/E of 33.24 is rich, offering little margin of safety if growth falters
• Zero dividend yield means no income buffer, only reliance on future appreciation
• Missing ROE, book value, and debt/equity data limits thorough fundamental analysis
• Latest quarter net margin of ~10.2% is modest and could be volatile

AI Analysis

This OSEL Devices business catches my eye, but I must be careful not to let the headline numbers seduce me. Sales grew 68.13% and profits 89.64% – those are exceptional figures, and a PEG of 0.42 suggests the market may still be underestimating the run-rate. The latest quarter shows ₹147 Cr sales and ₹15 Cr net profit, which translates to a margin of roughly 10.2%, not extraordinary but acceptable for a medical equipment player. What I like more is the ROCE of 31.14% – that tells me the company is earning a strong return on capital employed, a hallmark of a business with some pricing power or operational efficiency. Promoter holding at 65.21% also reassures me; the people running it have skin in the game. The Piotroski F-Score of 7/9 is solid, indicating healthy fundamentals across profitability, leverage, and efficiency. But I cannot ignore the price. At ₹561.60, the P/E is 33.24, which is not cheap for a company of this size. There is no dividend – zero yield – so my entire return depends on the growth continuing. I also have no visibility on book value, debt-to-equity, or ROE, which is uncomfortable for a Graham-style investor who likes to know what he owns. The 52-week range of ₹372 to ₹648 shows this stock can swing wildly. The FairStock score of 50/100 tells me to stay mixed. If growth decelerates, a 30-plus P/E will compress quickly. I would not build a position at this price without watching the next few quarters closely.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer